Dynavax Technologies Corporation news

   Watch this stock
Showing stories 11 - 20 of about 80   

Articles published

DVAX 1.48 -0.01 (-0.67%)
price chart
Key Announcements: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Dynavax ...
George S. Mack of The Life Sciences Report interviewed Vernon Bernardino, a senior analyst in MLV & Co. and got to know the analyst's view on the company Dynavax Technologies Corporation (NASDAQ:DVAX). Bernardino said that his company had a ...
Stocks to Track- Dynavax Technologies Corporation (NASDAQ:DVAX), KB ...  Techsonian (press release)
Related articles »  
Stocks in the Spotlight - Dynavax Technologies Corporation (DVAX), Gastar ...
Birmingham, West Midlands - (TechSonian) - 15th September 2014 �Dynavax Technologies Corporation (NASDAQ:DVAX)reported its financial results for the first quarter ended March 31, 2014.
Notable Movers-Dynavax Technologies Corporation (NASDAQ:DVAX ...
Dynavax Technologies Corporation (NASDAQ:DVAX) closed at $1.43 in the last trading session with the total traded volume of 951,660.00 shares.
Stocks in Hot Move- Caterpillar Inc. (NYSE:CAT), Dynavax Technologies ...
Dynavax Technologies Corporation (NASDAQ:DVAX) [Trend Analysis] reported that it has initiated a phase 1/2 clinical examination to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor or �TLR� 9 agonist, in adults ...
Trader's Buzzers � AuRico Gold Inc (NYSE:AUQ), Dynavax Technologies ...
Dynavax Technologies Corporation (NASDAQ:DVAX) reported its financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.
Stocks in Focus: Chimerix (NASDAQ:CMRX), Rite Aid Corporation (NYSE:RAD ...
On October 7, Dynavax Technologies Corporation (NASDAQ:DVAX) announced that Dino Dina, M.D, has resigned from the Board of Directors.
Stocks in News: Halliburton Company (NYSE:HAL), Peregrine Pharmaceuticals ...
Dynavax Technologies Corporation (NASDAQ:DVAX) said that it had commenced Phase 1/2 clinical study of TLR-9 Agonist Immunotherapy.
Stocks On Radar: Genetic Technologies Limited (ADR) (NASDAQ:GENE ...
Dynavax Technologies Corporation (NASDAQ:DVAX), on September 22, in a press release announced the completion of its enrolment for the Phase 3 clinical trials for HEPLISAV-B.
Related articles »  
Stocks in Focus � Gevo, Inc. (NASDAQ:GEVO), Dynavax Technologies ...
Gevo, Inc. (GEVO) reported that the United States Patent and Trademark Office (�USPTO�) issued an inter partes review decision rejecting the claims of Gevo's U.S.
Stocks Intraday Alert - Synergy Pharmaceuticals Inc (SGYP), Dynavax ...
Las Vegas, NV - 19 SEP, 2014 - (TechSonian) �Synergy Pharmaceuticals Inc (NASDAQ:SGYP) revealed that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic ...